HPHA Heidelberg Pharma AG

DGAP-News: Heidelberg Pharma AG: Annual General Meeting 2021 of Heidelberg Pharma Approves All Proposed Resolutions

DGAP-News: Heidelberg Pharma AG / Key word(s): AGM/EGM
Heidelberg Pharma AG: Annual General Meeting 2021 of Heidelberg Pharma Approves All Proposed Resolutions

18.05.2021 / 14:57
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

Annual General Meeting 2021 of Heidelberg Pharma Approves All Proposed Resolutions

Ladenburg, Germany, 18 May 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 98,40% to 99,99%) during the virtual Annual General Meeting today.

- Resolution on the formal approval of the actions of the members of the Executive Management Board and the Supervisory Board for the fiscal year 2020

- Resolution on the appointment of the auditor of the annual financial statements and the consolidated financial statements for the 2020/2021 fiscal year

- Resolution to revoke the Conditional Capital II, as well as to amend the Articles of Association accordingly

- Resolution on one further amendment to the Articles of Association regarding a change in the law

- Resolution concerning the remuneration of the members of the Executive Management and Supervisory Board

Presence (including postal voting) at the Annual General Meeting 2021 corresponded to 81,57% of the current share capital.

Heidelberg Pharma made use of the option provided by the German legislature in view of the coronavirus pandemic to conduct ordinary annual general meetings also in 2021 without the physical presence of shareholders or their proxies. Via a password-protected web service, registered shareholders can, among other things, follow the entire Annual General Meeting live via video and audio, exercise their voting rights and submit questions.

Dr. Jan Schmidt-Brand, Chief Executive Officer and Chief Financial Officer of Heidelberg Pharma AG, commented: "Today, we successfully held our second Annual General Meeting in virtual format. We are pleased that the shareholders or their proxies took advantage of this opportunity and submitted their questions electronically. On behalf of the Management Board, I would like to thank the shareholders of Heidelberg Pharma AG for their confidence in our Company and their long-standing support."

Please find more information about the Annual General Meeting including the voting results here: .

Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma.

Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at .

Contact
Heidelberg Pharma AG
Corporate Communications
Sylvia Wimmer
Tel.: -29
E-Mail: investors[at]hdpharma.com
Schriesheimer Str. 101, 68526 Ladenburg
IR/PR support
MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: 40
Mobil: 22
E-Mail: katja.arnold[at]mc-services.eu
 

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.



18.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: Heidelberg Pharma AG
Gregor-Mendel-Str. 22
68526 Ladenburg
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail:
Internet: -pharma.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1197937

 
End of News DGAP News Service

1197937  18.05.2021 

fncls.ssp?fn=show_t_gif&application_id=1197937&application_name=news&site_id=research_pool
EN
18/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Heidelberg Pharma AG

Thomas J. Schiessle
  • Thomas J. Schiessle

HPHA legt solide 2023 Finanzzahlen vor - ZircaixTM Royalty Deal als Ka...

Die Zahlen für FY 23 lagen im Rahmen unserer Erwartungen, wobei die abgegebene 24er Finanzprognose noch nicht die Vereinbarung mit HealthCare Royalty (HCRx) (März 24) über den Verkauf künftiger Lizenzzahlungen für ZircaixTM (TLX250-CDx) reflektiert. Durch den vereinbarten Mittelzufluss (insgesamt bis zu US$ 115 Mio. in drei Tranchen, davon US$ 25 Mio. bereits fällig) kann und will HPHA die F&E-Aktivitäten deutlich ausbauen und zügiger in Produkte skalieren. Die Bewertung des Geschäftsmodels fu...

 PRESS RELEASE

EQS-News: Heidelberg Pharma erhält Orphan Drug-Status von der FDA für ...

EQS-News: Heidelberg Pharma AG / Schlagwort(e): Sonstiges Heidelberg Pharma erhält Orphan Drug-Status von der FDA für ihren ATAC-Kandidaten HDP-101 27.03.2024 / 09:01 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG Heidelberg Pharma erhält Orphan Drug-Status von der FDA für ihren ATAC-Kandidaten HDP-101 Ladenburg, 27. März 2024 - Die Heidelberg Pharma AG (FWB: HPHA), ein klinischer Entwickler von innovativen Antikörper-Wirkstoff-Konjugaten (ADCs), gab heute bekannt, dass sie von der amerikanischen Zulassungsbehörd...

 PRESS RELEASE

EQS-News: Heidelberg Pharma granted orphan drug designation by FDA for...

EQS-News: Heidelberg Pharma AG / Key word(s): Miscellaneous Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 27.03.2024 / 09:01 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101 Ladenburg, Germany, 27 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and...

 PRESS RELEASE

EQS-News: Heidelberg Pharma announces financial figures and reports on...

EQS-News: Heidelberg Pharma AG / Key word(s): Annual Results Heidelberg Pharma announces financial figures and reports on successful business performance in 2023 25.03.2024 / 07:10 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma announces financial figures and reports on successful business performance in 2023 First efficacy data from the clinical trial with HDP-101 in multiple myeloma Expansion of the ADC technology platform to include further payloads New Management Board team Successful financing acti...

 PRESS RELEASE

EQS-News: Heidelberg Pharma gibt Finanzzahlen bekannt und berichtet üb...

EQS-News: Heidelberg Pharma AG / Schlagwort(e): Jahresergebnis Heidelberg Pharma gibt Finanzzahlen bekannt und berichtet über erfolgreichen Geschäftsverlauf 2023 25.03.2024 / 07:10 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG Heidelberg Pharma gibt Finanzzahlen bekannt und berichtet über erfolgreichen Geschäftsverlauf 2023 Erste Wirksamkeitsdaten der klinischen Studie mit HDP-101 im Multiplen Myelom Erweiterung der ADC-Technologieplattform um weitere Wirkstoffe Neues Vorstandsteam Erfolgreiche Finanzierungsa...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch